

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A combination comprising
 - (i) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, also named TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and
 - (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
2. (Original) The combination according to claim 1 comprising
 - (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and
 - (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
3. (Original) The combination according to claim 1 comprising
 - (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and
 - (ii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
4. (Original) The combination according to claim 1 comprising
 - (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt

- thereof; or a prodrug thereof; and
- (ii) a nucleoside reverse transcriptase inhibitor; and
- (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
5. (Original) The combination according to claim 1 comprising
- (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and
- (ii) a nucleoside reverse transcriptase inhibitor; and
- (iii) a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii) ; wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
6. (Currently Amended) The combination according to ~~any of claims 1—5~~claim 1, wherein TMC278 occurs in its E-isomeric form.
7. (Currently Amended) The combination according to ~~any of claims 1—6~~claim 1, wherein the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor or inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
8. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the nucleotide reverse transcriptase inhibitor is tenofovir or its prodrug tenofovir disoproxil fumarate.
9. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the nucleoside reverse transcriptase inhibitor is emtricitabine, racemic FTC, lamivudine (also named 3TC), abacavir or a pharmaceutically acceptable salt thereof.

10. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the nucleoside reverse transcriptase inhibitor is emtricitabine.
11. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the combination comprises
 - (i) TMC278 or a pharmaceutically acceptable salt, and
 - (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, and
 - (iii) emtricitabine.
12. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the nucleoside reverse transcriptase inhibitor is lamivudine.
13. (Original) The combination according to claim 8 wherein the combination comprises
 - (i) TMC278 or a pharmaceutically acceptable salt, and
 - (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, and
 - (iii) lamivudine.
14. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the nucleoside reverse transcriptase inhibitor is abacavir or a pharmaceutically acceptable salt thereof.
15. (Original) The combination according to ~~claim~~claim 14 wherein the combination comprises
 - (i) TMC278 or a pharmaceutically acceptable salt, and
 - (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, and
 - (iii) abacavir or a pharmaceutically acceptable salt thereof.
16. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the combination comprises
 - (i) TMC278 or a pharmaceutically acceptable salt, and
 - (ii) lamivudine, and
 - (iii) emtricitabine.

17. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the combination comprises
- (i) TMC278 or a pharmaceutically acceptable salt, and
 - (ii) abacavir, or a pharmaceutically acceptable salt thereof; and
 - (iii) emtricitabine.
18. (Currently Amended) The combination according to ~~any one of claims 1 to 7~~claim 1 wherein the combination comprises
- (i) TMC278 or a pharmaceutically acceptable salt, and
 - (ii) lamivudine, and
 - (iii) abacavir, or a pharmaceutically acceptable salt thereof.
19. (Currently Amended) The combination according to ~~any one of claims 1 to 18~~claim 1 wherein weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/4 to 4/1.
20. (Currently Amended) A product containing a combination as claimed in ~~any of claims 1 to 19~~claim 1 as a combined preparation for simultaneous, separate or sequential use against HIV infection.
21. (Currently Amended) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as claimed in ~~any of claims 1 to 18~~claim 1.
22. (Original) The formulation of claim 21 comprising as active ingredients (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a nucleotide reverse transcriptase inhibitor.
23. (Currently Amended) A combination as claimed in ~~any one of claims 1 to 18~~claim 1 for use as a medicine.

24. (Currently Amended) Use of a combination as claimed in ~~any one of claims 1 to 18~~claim 1 for the manufacture of a medicament for the prevention of HIV infection or transmission via sexual intercourse or related intimate contact between partners.